219 related articles for article (PubMed ID: 33650720)
1. Ubiquitin-specific protease 7 as a potential therapeutic target in dogs with hematopoietic malignancies.
Pawlak A; Bajzert J; Bugiel K; Hernández Suárez B; Kutkowska J; Rapak A; Hildebrand W; Obmińska-Mrukowicz B; Freire R; Smits VAJ
J Vet Intern Med; 2021 Mar; 35(2):1041-1051. PubMed ID: 33650720
[TBL] [Abstract][Full Text] [Related]
2. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
[TBL] [Abstract][Full Text] [Related]
3. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
[TBL] [Abstract][Full Text] [Related]
4. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
5. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
[TBL] [Abstract][Full Text] [Related]
6. USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.
Saha G; Sarkar S; Mohanta PS; Kumar K; Chakrabarti S; Basu M; Ghosh MK
Oncogene; 2022 Nov; 41(47):5061-5075. PubMed ID: 36243803
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.
Colland F; Formstecher E; Jacq X; Reverdy C; Planquette C; Conrath S; Trouplin V; Bianchi J; Aushev VN; Camonis J; Calabrese A; Borg-Capra C; Sippl W; Collura V; Boissy G; Rain JC; Guedat P; Delansorne R; Daviet L
Mol Cancer Ther; 2009 Aug; 8(8):2286-95. PubMed ID: 19671755
[TBL] [Abstract][Full Text] [Related]
8. USP7: Target Validation and Drug Discovery for Cancer Therapy.
Zhou J; Wang J; Chen C; Yuan H; Wen X; Sun H
Med Chem; 2018; 14(1):3-18. PubMed ID: 29065837
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.
Carreira LD; Oliveira RI; Moreira VM; Salvador JAR
Expert Opin Ther Targets; 2023; 27(11):1043-1058. PubMed ID: 37789645
[TBL] [Abstract][Full Text] [Related]
10. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
[TBL] [Abstract][Full Text] [Related]
11. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
12. Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.
Zhang W; Sartori MA; Makhnevych T; Federowicz KE; Dong X; Liu L; Nim S; Dong A; Yang J; Li Y; Haddad D; Ernst A; Heerding D; Tong Y; Moffat J; Sidhu SS
J Mol Biol; 2017 Nov; 429(22):3546-3560. PubMed ID: 28587923
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent and Selective Degrader for USP7.
Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
[TBL] [Abstract][Full Text] [Related]
14. USP7 as an emerging therapeutic target: A key regulator of protein homeostasis.
Guo NJ; Wang B; Zhang Y; Kang HQ; Nie HQ; Feng MK; Zhang XY; Zhao LJ; Wang N; Liu HM; Zheng YC; Li W; Gao Y
Int J Biol Macromol; 2024 Apr; 263(Pt 1):130309. PubMed ID: 38382779
[TBL] [Abstract][Full Text] [Related]
15. Targeting senescent HDF with the USP7 inhibitor P5091 to enhance DFU wound healing through the p53 pathway.
Zhang S; Meng N; Liu S; Ruan J; Li H; Xu X; Ruan Q; Xie W
Biochem Biophys Res Commun; 2024 Aug; 722():150149. PubMed ID: 38788355
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-Specific Peptidase 7: A Novel Deubiquitinase That Regulates Protein Homeostasis and Cancers.
Zhou L; Ouyang T; Li M; Hong T; Mhs A; Meng W; Zhang N
Front Oncol; 2021; 11():784672. PubMed ID: 34869041
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of USP7 induce apoptosis through oxidative and endoplasmic reticulum stress in cancer cells.
Lee G; Oh TI; Um KB; Yoon H; Son J; Kim BM; Kim HI; Kim H; Kim YJ; Lee CS; Lim JH
Biochem Biophys Res Commun; 2016 Jan; 470(1):181-186. PubMed ID: 26768359
[TBL] [Abstract][Full Text] [Related]
18. DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
Hernández-Pérez S; Cabrera E; Salido E; Lim M; Reid L; Lakhani SR; Khanna KK; Saunus JM; Freire R
Oncogene; 2017 Aug; 36(33):4802-4809. PubMed ID: 28288134
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
